Biblio Discovery — Demo Discovery Service

44 hasil untuk "Alessandro Inno"

Menampilkan 1–20 · 0,35 detik · RSS

  1. Artikel Jurnal

    Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report

    Alessandro Inno; Emanuela Lattuada; Giovanni Foti dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    Activity and safety data of chemo-immunotherapy for patients with metastatic NSCLC and known HIV infection are still limited, since HIV-positive patients were generally excluded from clinical trials. Here we report the case of a metastatic NSCLC patient with HIV infection and undetectable viral…

  2. Artikel Jurnal

    Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients

    Alessandro Inno; Andrea Chiampan; Laura Lanzoni dkk.

    Frontiers in Cardiovascular Medicine, Vol. 8 · 2021 · Inggris · DOAJ Scopus

    In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of…

  3. Artikel Jurnal Teks lengkap

    Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials

    Andrea Messori; Andrea Ossato; Lorenzo Gasperoni dkk.

    Current Oncology, Vol. 32 No. 1 · 2025 · Inggris · DOAJ Scopus

    Background: Immune checkpoint inhibitors (ICIs), either alone or in combination with platinum-based chemotherapy, are effective in the first-line treatment of metastatic, non-oncogene-addicted, non-small cell lung cancer (NSCLC). However, when NSCLC patients progress, the efficacy of available…

  4. Artikel Jurnal

    Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report

    Alessandro Inno; Fabiana Marchetti; Matteo Valerio dkk.

    Drug Target Insights, Vol. 17 No. 1 · 2023 · Inggris · DOAJ Scopus

    In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and…

  5. Artikel Jurnal

    First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression

    Alessandro Inno; Giuseppe Bogina; Giulio Settanni dkk.

    Drug Target Insights, Vol. 17 No. 1 · 2023 · Inggris · DOAJ Scopus

    Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (MET) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients with this condition, while evidence on safety and…

  6. Artikel Jurnal Teks lengkap

    Dual-Energy CT in Oncologic Imaging

    Giovanni Foti; Giorgio Ascenti; Andrea Agostini dkk.

    Tomography, Vol. 10 No. 3 · 2024 · Inggris · DOAJ Scopus

    Dual-energy CT (DECT) is an innovative technology that is increasingly widespread in clinical practice. DECT allows for tissue characterization beyond that of conventional CT as imaging is performed using different energy spectra that can help differentiate tissues based on their specific…

  7. Artikel Jurnal

    Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

    Vera Damuzzo; Lorenzo Gasperoni; Luna Del Bono dkk.

    Frontiers in Oncology, Vol. 15 · 2025 · Inggris · DOAJ Scopus

    IntroductionAnaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, including alectinib, brigatinib, ensartinib, envonalkib, and lorlatinib, have shown better efficacy than…

  8. Artikel Jurnal

    SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs

    Lorenzo Belluomini; Lorenzo Calvetti; Alessandro Inno dkk.

    Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

    Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or…

  9. Artikel Jurnal

    Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis

    Alessandro Inno; Antonello Veccia; Giorgio Madonia dkk.

    Frontiers in Cardiovascular Medicine, Vol. 11 · 2024 · Inggris · DOAJ Scopus

    IntroductionCombinations of immune checkpoint inhibitors (ICIs) and angiogenesis inhibitors (AIs) have been investigated for the treatment of several tumor types. Both ICIs and AIs may lead to cardiovascular adverse events, and their combination may potentially increase the risk for cardiovascular…

  10. Artikel Jurnal Teks lengkap

    PIK3CA Alterations in NSCLC: Clinical Characteristics of a “Neglected” Population of Oncogene-Addicted Patients

    Sabrina Rossi; Arianna Pagliaro; Silvia Masini dkk.

    Biomedicines, Vol. 14 No. 2 · 2026 · Inggris · DOAJ Scopus

    Background/Objectives: Alterations of the phosphatidylinositol 3-kinase catalytic subunit alpha gene (PIK3CA) are identified in approximately 2–4% of non-small cell lung cancer (NSCLC) cases; however, their biological and clinical relevance in NSCLC remains incompletely understood. This study aimed…

  11. Artikel Jurnal

    5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment

    Mojtaba Miladinia; Mina Jahangiri; Sharon Jackson White dkk.

    Trials, Vol. 25 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Cancer-related fatigue (CRF) is still undertreated in most patients, as evidence for pharmacological treatments is limited and conflicting. Also, the efficacy of the pharmacological agents relative to each other is still unclear. Therefore, medications that may potentially…

  12. Artikel Jurnal

    Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison

    Luna Del Bono; Andrea Ossato; Lorenzo Gasperoni dkk.

    Frontiers in Oncology, Vol. 16 · 2026 · Inggris · DOAJ Scopus

    BackgroundOsimertinib (Osi) has long represented the standard first-line treatment for metastatic EGFR-mutated non-small cell lung cancer. Recently, two randomized phase 3 trials demonstrated that osimertinib plus platinum-based chemotherapy (Osi+CT) and amivamtamab plus lazertinib (Ami+Laz)…

  13. Artikel Jurnal Teks lengkap

    Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study

    Stefania Gori; Alessandro Inno; Valentina Rossi dkk.

    PLOS ONE, Vol. 11 No. 5 · 2016 · Inggris · PLOS Scopus

    Background: There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods: Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from…

    Juga tersedia di: DOAJ

  14. Artikel Jurnal Teks lengkap

    Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism

    Vincenzo Quagliariello; Maria Laura Canale; Irma Bisceglia dkk.

    Biomedicines, Vol. 12 No. 8 · 2024 · Inggris · DOAJ Scopus

    Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology described several shared risk factors that predispose patients to both cardiovascular disease and cancer. Post-acute COVID-19 syndrome is a chronic condition…

  15. Artikel Jurnal

    Sodium–glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk

    Vincenzo Quagliariello; Massimiliano Berretta; Irma Bisceglia dkk.

    Journal of Translational Medicine, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Background Hormone receptor–positive breast cancer (HR+ BC) represents the most common breast cancer subtype and is increasingly characterized by long-term survivorship complicated by substantial cardiometabolic and cardiovascular morbidity. Endocrine therapies, including aromatase…

  16. Artikel Jurnal

    The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy

    Alessandro Inno; Marta Peri; Monica Turazza dkk.

    Frontiers in Oncology, Vol. 12 · 2023 · Inggris · DOAJ Scopus

    IntroductionThe role of fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in early breast cancer treated with preoperative systemic therapy (PST) is not yet established in clinical practice. PET parameters have aroused great interest in the recent years, as…

  17. Artikel Jurnal

    Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

    Vincenzo Quagliariello; Margherita Passariello; Annabella Di Mauro dkk.

    Frontiers in Cardiovascular Medicine, Vol. 9 · 2022 · Inggris · DOAJ Scopus

    BackgroundImmune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and…